Competition. Some of our competitors have initiated clinical trials for GvHD, solid tumors and multiple myeloma, settings in which our iNKT cell therapy platform is currently being investigated. We are also aware of competitors pursuing cell therapy drug candidates, including but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies th...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134813 | EDGAR | 74K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-041379 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034672 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0000950170-23-009762 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0001564590-22-011026 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-282905 | EDGAR | 16K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108894 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072789 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127033 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096142 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059081 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063851 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040958 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021191 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021565 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029503 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001564590-22-020146 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-133346 | EDGAR | 1K words |
| 2026-03-27 | 0001193125-26-127931 | EDGAR | — |
| 2026-03-19 | 0001193125-26-116219 | EDGAR | — |
| 2026-01-02 | 0001193125-26-000916 | EDGAR | — |
| 2025-12-08 | 0001193125-25-311229 | EDGAR | — |
| 2025-09-29 | 0001193125-25-221863 | EDGAR | — |
| 2025-08-14 | 0001171843-25-005405 | EDGAR | — |
| 2025-07-15 | 0001193125-25-159017 | EDGAR | — |
| 2025-07-14 | 0000950170-25-095460 | EDGAR | — |
| 2025-06-18 | 0000950170-25-087888 | EDGAR | — |
70 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001840229 |
| Ticker | INKT |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.minktherapeutics.com |
| Listed | 2021-10-15 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report